This conference is provided free of charge to attendees, but registration is required. Register Now

Time Description Speaker
7:45 am Registration/Breakfast
8:30am Welcome Djordje Atanackovic, MD
8:35am Toxicities after CD19-Specific CAR-T Cell Therapy Kevin Hay, MD
9:10am CD229, an Ideal Target for the Immunotherapy of Multiple Myeloma Tim Luetkens, MD
9:35 am Can a non-immunogenic tumor be transformed to an immunogenic one? -An engineering of tumor cells Mingnan Chen, PhD
10:00am Break
10:20am What we learned from bench to bedside with
the neuroblastoma targeting CD171-specific
Annette Künkele, MD
11:05am A novel CAR T cell approach for T cell
Djordje Atanackovic, MD
11:30am The Promise of Immunotherapy in Bladder
Sumati Gupta, MD
11:55am MAITing adaptive and innate immunity against
Cole Anderson, PhD
12:20pm Lunch
1:20pm Genetically engineered T cells for the
Immunotherapy for HER2+ Sarcoma
Chris DeRenzo, MD, MBA
1:55pm MSI and Neoantigens Roger Wolff, PhD
2:20pm Defining the role of miR-155 during tumor
immunity at single cell resolution
Ryan O’Connell, PhD
2:45pm Break
3:05pm T-cell therapy targeting MAGE-A3 in solid
Yong-Chen William Lu, PhD
3:40pm Oncolytic viruses turning up the heat in tumors Robert Andtbacka, MD,CM, FACS FRCSC
3:55pm TCR affinity in the regulation of anti-tumor
immune responses
Matthew Williams, PhD
4:30pm Summary Djordje Atanackovic, MD

Please contact Calle Laplant at or 801-585-3599 if you have questions or need additional information.